CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
CLBS16biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03508609
NCT03508609Phase 2Completed
CompareCT.gov

An Open-Label Exploratory Clinical Study to Evaluate the Safety and Potential Bioactivity of CLBS16 in Patients With Coronary Microvascular Dysfunction (CMD) and Without Obstructive Coronary Artery Disease

Lisata Therapeutics, Inc.·interventional·Posted Apr 26, 2018·Updated Jan 8, 2021

In Brief

A Phase 2 clinical trial evaluating CLBS16 for Coronary Microvascular Dysfunction. Completed, enrolled 20 participants across 2 sites.

Detailed Summary

This clinical trial will explore the safety and effect of GCSF-mobilized autologous ex vivo selected CD34 cells for the treatment of CMD in adults currently experiencing angina and with no obstructive coronary artery disease. Eligible subjects will receive a single intracoronary infusion of CLBS16.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Microvascular Dysfunction
CountriesUnited States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI), Cedars-Sinai Medical Center, Mayo Clinic

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 26, 2018
Enrollment StartApr 19, 2018
Primary CompletionDec 10, 2019
Study CompletionMay 5, 2020
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.2 years ago

Interventions

CLBS16biological

GCSF-mobilized autologous CD34 cells